Unique service for de novo discovery of the best peptide binders for your target protein of interest
Therapeutic peptides are becoming increasingly important in the pharma industry. They currently represent a market value of 28 billion USD, with an annual growth rate of at least 10% over the next five years. Peptide therapeutics based on highly constrained peptides are a unique class of drugs that possess the therapeutic properties of small molecule drugs and biologics, but are distinguished from both at the molecular level.
Pepscan offers proprietary peptide technologies, peptide chemistry expertise and a strong track record in contract research and R&D collaborations to scientists looking for the best constrained peptide binders for their target protein of interest. Pepscan’s business model for peptide discovery projects is fee-for-service, including several options for success-based fees.
Discover highly constrained peptides with enhanced affinity, selectivity and proteolytic stability
We have developed a unique technology to discover new highly constrained peptides. By using our proprietary CLIPSTM technology, we generate highly constrained redox-stable peptides with enhanced affinity, selectivity and proteolytic stability suited for diagnostic and therapeutic applications.
Phage display facilitates the de novo discovery of peptides against any target of interest by exploring DNA-encoded peptide libraries. This powerful technology can screen libraries of billions of different peptides in less than four weeks.
Key benefits of Pepscan’s CLIPSTM Phage Display technology
- By combining the world’s largest portfolio of CLIPSTM scaffolds with our high-quality next-generation sequencing-validated phage-display library with ~1010 CLIPSTM variants, we significantly increase the chance of identifying potent ligands for your protein of interest.
- We possess a hi-sense peptide platform for the structural fine-tuning of CLIPSTM-constrained peptides, with a capacity exceeding 70,000 peptides per month.
- CLIPS™-constrained redox-stable peptides are the best of both worlds, combining the benefits of both biologicals and small molecule therapeutics.
- Our phage-display platform is fully optimized for screening CLIPSTM peptides and can screen billions of different peptides in less than four weeks.
- We offer the complete CLIPSTM peptide discovery pipeline: hit validation, binding-site identification and lead optimization on proprietary peptide arrays, as well as both R&D and clinical peptide synthesis.
- Our highly trained staff has years of experience in peptide display, synthesis, design, optimization and the molecular recognition of peptides.
- Our proven and proprietary CLIPSTM technology puts you at the forefront of new peptide therapeutics.
Pepscan’s team of experts
Michael Goldflam, PhD – Director Peptide Discovery – Michael completed his Master degree in Organic Chemistry at the Hamburg University, Germany. After working with Prof. Hiroaki Suga at the University of Tokio he received his PhD title while working in Prof. Ernest Giralt’s research group at IRB Barcelona on combined use of NMR and computational tools for fragment- based drug discovery targeting protein-protein interactions. After working at Cambridge University Michael joined Pepscan in 2016 where he further specialized and joined in the development of Pepscan’s Peptide Discovery Phage Display platform.
Sangram Kale, PhD – Scientist Peptide Discovery – Sangram completed his Master and PhD degrees in Organic Chemistry at the University of Pune, India. After working for the National Chemical Laboratory in Pune, Sangram moved to Europe and started working as a postdoctoral researcher in the research groups of Prof. Christian Heinis at École Polytechnique Fédérale de Lausanne. Following up on this position in Lausanne, he started working at the Max Planck Institute for Medical Research with Prof. Kai Johnsson. Sangram’s focus is on using his experience and expertise for the further expansion of Pepscan’s peptide-phage discovery technology and the management of internal and external projects.